TY - JOUR
T1 - Diagnosis and treatment of cancer-related anemia
AU - Gilreath, Jeffrey A.
AU - Stenehjem, David D.
AU - Rodgers, George M.
PY - 2014/2
Y1 - 2014/2
N2 - Cancer-related anemia (CRA) is due to multiple etiologies, including chemotherapy-induced myelosuppression, blood loss, functional iron deficiency, erythropoietin deficiency due to renal disease, marrow involvement with tumor as well as other factors. The most common treatment options for CRA include iron therapy, erythropoietic-stimulating agents (ESAs), and red cell transfusion. Safety concerns as well as restrictions and reimbursement issues surrounding ESA therapy for CRA have resulted in suboptimal treatment. Similarly, many clinicians are not familiar or comfortable using intravenous iron products to treat functional iron deficiency associated with CRA. This article summarizes our approach to treating CRA and discusses commonly encountered clinical scenarios for which current clinical guidelines do not apply.
AB - Cancer-related anemia (CRA) is due to multiple etiologies, including chemotherapy-induced myelosuppression, blood loss, functional iron deficiency, erythropoietin deficiency due to renal disease, marrow involvement with tumor as well as other factors. The most common treatment options for CRA include iron therapy, erythropoietic-stimulating agents (ESAs), and red cell transfusion. Safety concerns as well as restrictions and reimbursement issues surrounding ESA therapy for CRA have resulted in suboptimal treatment. Similarly, many clinicians are not familiar or comfortable using intravenous iron products to treat functional iron deficiency associated with CRA. This article summarizes our approach to treating CRA and discusses commonly encountered clinical scenarios for which current clinical guidelines do not apply.
UR - http://www.scopus.com/inward/record.url?scp=84893910207&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84893910207&partnerID=8YFLogxK
U2 - 10.1002/ajh.23628
DO - 10.1002/ajh.23628
M3 - Review article
C2 - 24532336
AN - SCOPUS:84893910207
SN - 0361-8609
VL - 89
SP - 203
EP - 212
JO - American Journal of Hematology
JF - American Journal of Hematology
IS - 2
ER -